Company profile

Ascendis Pharma A/S

NASDAQ:ASNDBiotechnology: Pharmaceutical Preparations

Drug pipeline (3)

Asset	Stage	Revenue	Trials	Status
Navepegritide	approved	—	3	approved
PALOPEGTERIPARATIDE	approved	—	0	—
ACP-001	phase2	—	3	no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (19)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06732895	phase2	recruiting	2024-12-10	2027-08-01	Ascendis Pharma A/S	A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
NCT05598320	phase2_3	completed	2023-03-03	2024-08-09	Ascendis Pharma Growth Disorders A/S	A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
NCT06079398	phase2	recruiting	2024-01-23	2027-12-01	Ascendis Pharma A/S	A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT05929807	phase2_3	enrolling_by_invitation	2023-06-21	2039-01-01	Ascendis Pharma Growth Disorders A/S	A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
NCT04085523	phase2	completed	2020-06-24	2022-09-27	Ascendis Pharma A/S	A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

FDA applications (3)

Application

Type

Applicant

Products

BLA 761177

BLA

Ascendis Pharma Endocrinology Division A/S

NDA 216490

NDA

ASCENDIS PHARMA BONE DISEASES AS

NDA 219164

NDA

ASCENDIS PHARMA GROWTH DISORDERS AS